| Literature DB >> 7287223 |
P J Shearman, B M Longenecker.
Abstract
Monoclonal antibodies were used to probe the cell surface of organ-selected metastatic variant cells. Previously we defined a liver metastasis-associated antigen (LMAA) by means of the reaction of a monoclonal antibody with a liver metastasis selected tumour variant cell line, MDCC-AL2. The monoclonal anti-LMAA antibodies specifically inhibit liver metastasis of AL2. There is a correlated, clonal variation in LMAA expression and liver metastasis in both the AL2 cell line and an overy-selected metastatic variant MDCC-AL3. The variation in liver metaatatic ability is thought to represent clonal progression of the tumour cell lines. The LMAA probably represents only one of the ways in which a tumour cell may give rise to a live metastasis. Two hypotheses are discussed utilizing the LMAA in a functional role in the specific trapping of metastatic tumour cells in the liver or the successful colonization of the liver by metastatic tumour cells.Entities:
Mesh:
Substances:
Year: 1981 PMID: 7287223 DOI: 10.1002/ijc.2910270319
Source DB: PubMed Journal: Int J Cancer ISSN: 0020-7136 Impact factor: 7.396